Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921

PURPOSE: Patients with high-risk prostate cancer after radical prostatectomy are at risk for death. Adjuvant androgen-deprivation therapy (ADT) may reduce this risk. We hypothesized that the addition of mitoxantrone and prednisone (MP) to adjuvant ADT could reduce mortality compared with adjuvant AD...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Hussain, Maha, Tangen, Catherine M., Thompson, Ian M., Swanson, Gregory P., Wood, David P., Sakr, Wael, Dawson, Nancy A., Haas, Naomi B., Flaig, Thomas W., Dorff, Tanya B., Lin, Daniel W., Crawford, E. David, Quinn, David I., Vogelzang, Nicholas J., Glode, L. Michael
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2018
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5959197/
https://ncbi.nlm.nih.gov/pubmed/29624463
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.76.4126
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados